LDD™ is our exclusive brand of Low Dose Dipyridamole. LDD™ capsules contain 2 mg of dipyridamole per capsule. Dipyridamole was approved by the US FDA in 1961 to prevent blood clots, and more recently it was additionally approved for preventing strokes. The typical daily dose is 200 - 400 mg. LDD™ refers to using dipyridamole at very low doses, typically less than 10 mg daily.
Low dose dipyridamole is being studied for treating insomnia (sleep disorders), dry eye disease (DED), pain disorders including fibromyalgia, viral infections, and anxiety. LDD™ was discovered by researchers in Israel, is patented worldwide, and is sold under license from the patent holders. The concept of LDD™ bears great resemblance to that of LDN (low dose naltrexone) in that low dose is essential for therapy success. LDD™ too provides benefits only at low doses that do not occur at high doses. The exact novel mechanism of action of low dose dipyridamole is still being researched.
Did you know?
Dipyridamole comes in various forms. In high dose (25 mg - 200 mg pills) it is sold under the brand names Persantin®, Persantine®, Curantyl®, Cardoxin®, and Aggrenox®. It is also available in injectable form (10 mg injections). Dipyridamole is being developed in eye drop form for treating eye disorders. Low dose dipyridamole is available under license exclusively from us, under our trade name LDD™.